
Altamira Therapeutics Ltd. – NASDAQ:EARS
Altamira Therapeutics Ltd. stock price today
Altamira Therapeutics Ltd. stock price monthly change
Altamira Therapeutics Ltd. stock price quarterly change
Altamira Therapeutics Ltd. stock price yearly change
Altamira Therapeutics Ltd. key metrics
Market Cap | 4.21M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -228.57 |
Revenue | N/A |
EBITDA | 2.02M |
Income | -15.83M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAltamira Therapeutics Ltd. stock price history
Altamira Therapeutics Ltd. stock forecast
Altamira Therapeutics Ltd. financial statements
Sep 2022 | -458.69K | -9.61M | 2095.32% |
---|---|---|---|
Dec 2022 | 0 | -802.07K | |
Mar 2023 | 52.73K | -2.71M | -5139.89% |
Jun 2023 | 52.73K | -2.71M | -5139.89% |
Mar 2023 | 6203962 | 8.02M | 129.41% |
---|---|---|---|
Jun 2023 | 6203962 | 8.02M | 129.41% |
Sep 2023 | 7694259 | 888.91K | 11.55% |
Dec 2023 | 7694259 | 1.23M | 16.06% |
Sep 2022 | -1.54M | -304.13K | 1.64M |
---|---|---|---|
Dec 2022 | -1.54M | -304.13K | 1.64M |
Mar 2023 | -3.85M | 120 | 3.84M |
Jun 2023 | -3.85M | 120 | 3.84M |
Altamira Therapeutics Ltd. alternative data
Aug 2023 | 8 |
---|---|
Sep 2023 | 8 |
Oct 2023 | 8 |
Nov 2023 | 8 |
Dec 2023 | 8 |
Jan 2024 | 8 |
Feb 2024 | 8 |
Mar 2024 | 8 |
Apr 2024 | 8 |
May 2024 | 8 |
Jun 2024 | 8 |
Jul 2024 | 8 |
Altamira Therapeutics Ltd. other data
Quarter | Transcript |
---|---|
Q2 2020 17 Sep 2020 | Q2 2020 Earnings Call Transcript |
Q2 2019 15 Aug 2019 | Q2 2019 Earnings Call Transcript |
Q4 2018 14 Mar 2019 | Q4 2018 Earnings Call Transcript |
Q3 2018 15 Nov 2018 | Q3 2018 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Thomas Meyer (1968) Founder, Chairman, Chief Executive Officer & MD | $458,310 |
Mr. Elmar Schaerli CPA Chief Financial Officer |
-
What's the price of Altamira Therapeutics Ltd. stock today?
One share of Altamira Therapeutics Ltd. stock can currently be purchased for approximately $3.05.
-
When is Altamira Therapeutics Ltd.'s next earnings date?
Unfortunately, Altamira Therapeutics Ltd.'s (EARS) next earnings date is currently unknown.
-
Does Altamira Therapeutics Ltd. pay dividends?
No, Altamira Therapeutics Ltd. does not pay dividends.
-
How much money does Altamira Therapeutics Ltd. make?
Altamira Therapeutics Ltd. has a market capitalization of 4.21M.
-
What is Altamira Therapeutics Ltd.'s stock symbol?
Altamira Therapeutics Ltd. is traded on the NASDAQ under the ticker symbol "EARS".
-
What is Altamira Therapeutics Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Altamira Therapeutics Ltd.?
Shares of Altamira Therapeutics Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Altamira Therapeutics Ltd.'s key executives?
Altamira Therapeutics Ltd.'s management team includes the following people:
- Dr. Thomas Meyer Founder, Chairman, Chief Executive Officer & MD(age: 57, pay: $458,310)
- Mr. Elmar Schaerli CPA Chief Financial Officer
-
Is Altamira Therapeutics Ltd. founder-led company?
Yes, Altamira Therapeutics Ltd. is a company led by its founder Dr. Thomas Meyer.
-
How many employees does Altamira Therapeutics Ltd. have?
As Jul 2024, Altamira Therapeutics Ltd. employs 8 workers.
-
When Altamira Therapeutics Ltd. went public?
Altamira Therapeutics Ltd. is publicly traded company for more then 11 years since IPO on 6 Aug 2014.
-
What is Altamira Therapeutics Ltd.'s official website?
The official website for Altamira Therapeutics Ltd. is aurismedical.com.
-
Where are Altamira Therapeutics Ltd.'s headquarters?
Altamira Therapeutics Ltd. is headquartered at Bahnhofstrasse 21, Zug, ZUG.
-
How can i contact Altamira Therapeutics Ltd.?
Altamira Therapeutics Ltd.'s mailing address is Bahnhofstrasse 21, Zug, ZUG and company can be reached via phone at +41 61 201 13 50.
Altamira Therapeutics Ltd. company profile:

Altamira Therapeutics Ltd.
aurismedical.comNASDAQ
8
Biotechnology
Healthcare
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.
Zug, ZUG HM 11
CIK: 0001601936
ISIN: BMG070252017
CUSIP: G07025201